Letrozole 2.5

Products description: Unique Pharma - Letrozole 2.5

This overview synthesizes information on Letrozole, the active substance reportedly in Unique Pharma - Letrozole 2.5, from a limited set of key scientific literature and reputable databases. The information presented aims to be current based on sources accessible and reviewed up to August 8, 2025. Medical knowledge and guidelines are constantly evolving; always consult primary sources and healthcare professionals for the absolute most current information.

Letrozole is a non-steroidal aromatase inhibitor, a class of medication used primarily in the treatment of breast cancer. It works by blocking the production of estrogen in the body, thereby slowing or stopping the growth of certain types of breast cancer cells that depend on estrogen to grow [1, 3].

⚕️Established Medical Uses for Letrozole

Letrozole is a well-established and approved medication with specific therapeutic applications, mainly in oncology [1, 3]:

• Adjuvant treatment of hormone-receptor-positive early breast cancer in postmenopausal women.
• Extended adjuvant treatment for postmenopausal women with early breast cancer who have completed 5 years of tamoxifen therapy.
• First-line treatment for hormone-receptor-positive advanced or metastatic breast cancer in postmenopausal women.
• Used off-label to induce ovulation in women with infertility [4, 5].

🔬Mechanism of Action (Scientifically Described for Letrozole)

The primary mechanism of action for letrozole is its potent and competitive inhibition of the aromatase enzyme [1, 2]:

• Aromatase Inhibition: Aromatase is the key enzyme responsible for converting androgens (like testosterone) into estrogens in peripheral tissues, such as fat, muscle, and the liver. In postmenopausal women, this is the main source of estrogen production.
• Estrogen Reduction: By binding to the aromatase enzyme, letrozole prevents this conversion, leading to a significant reduction in circulating estrogen levels.
• Antitumor Effect: In hormone-receptor-positive breast cancers, estrogen acts as a growth factor. The reduction in estrogen levels helps to starve the cancer cells, thereby slowing or stopping their growth.

⚠️Safety and Adverse Effects (Balanced & Fact-Based for Letrozole)

The use of Letrozole (the active substance in Unique Pharma - Letrozole) is associated with potential side effects, primarily related to the suppression of estrogen [1, 3, 4]:

• Common Side Effects: Hot flashes, joint pain (arthralgia), muscle pain, fatigue, and headache are frequently reported.
• Skeletal Health: Lower estrogen levels can lead to a decrease in bone mineral density, increasing the risk of osteoporosis and fractures.
• Cardiovascular Risks: There may be an increased risk of cardiovascular events, such as heart attack and stroke.
• Other Effects: Nausea, dizziness, and swelling of the arms, hands, feet, ankles, or lower legs can also occur.

These effects are generally managed through medical supervision and lifestyle adjustments.

💉Dosage and Administration (General Medical Context for Letrozole)

Letrozole is administered orally, typically as a tablet taken once a day. The dosage and duration of treatment are determined by a healthcare professional based on the specific medical indication and the patient's overall health [1, 3]:

• Individualized Dosing: The standard dose for breast cancer treatment is 2.5 mg daily. The duration of therapy can be for a period of 5 years or more.
• Professional Monitoring: Regular monitoring of bone density, cholesterol levels, and general health is crucial to manage and mitigate potential long-term side effects.

📚References

1. Cancer Research UK. Letrozole (Femara). Accessed August 8, 2025. https://www.cancerresearchuk.org/about-cancer/treatment/drugs/letrozole-femara
2. Pubmed. Letrozole: a novel potent oral aromatase inhibitor for the treatment of estrogen-dependent breast cancer. Accessed August 8, 2025. https://pubmed.ncbi.nlm.nih.gov/9469328/
3. PMC. Letrozole for ovulation induction and other infertility treatments: a systematic review and meta-analysis. Accessed August 8, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC8245002/
4. Pubmed. Side-effects of letrozole in postmenopausal women with breast cancer. Accessed August 8, 2025. https://pubmed.ncbi.nlm.nih.gov/15161328/
5. Academic.oup.com. Letrozole versus clomiphene citrate for ovulation induction in women with polycystic ovary syndrome: A systematic review and meta-analysis. Accessed August 8, 2025. https://academic.oup.com/ejendo/article-abstract/158/5/741/6676004?redirectedFrom=PDF

This information is not medical advice. Consult with a doctor to use this product.